Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences.

McDevitt PJ, Schneck JL, Diaz E, Hou W, Huddleston MJ, Matico RE, McCormick PM, Kirkpatrick RB.

Protein Expr Purif. 2019 Jul 12:105455. doi: 10.1016/j.pep.2019.105455. [Epub ahead of print]

PMID:
31306746
2.

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2019 Jun;570(7761):E53. doi: 10.1038/s41586-019-1265-5.

PMID:
31142845
3.

Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy.

Hickey JW, Dong Y, Chung JW, Salathe SF, Pruitt HC, Li X, Chang C, Fraser AK, Bessell CA, Ewald AJ, Gerecht S, Mao HQ, Schneck JP.

Adv Mater. 2019 Jun;31(23):e1807359. doi: 10.1002/adma.201807359. Epub 2019 Apr 10.

PMID:
30968468
4.

Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes.

Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW, Schneck JP, Gerecht S.

Matrix Biol. 2019 Feb 16. pii: S0945-053X(18)30458-X. doi: 10.1016/j.matbio.2019.02.003. [Epub ahead of print]

PMID:
30776427
5.

High-affinity T cell receptors for adoptive cell transfer.

Isser A, Schneck JP.

J Clin Invest. 2019 Jan 2;129(1):69-71. doi: 10.1172/JCI125471. Epub 2018 Dec 10.

6.

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles.

Hickey JW, Schneck JP.

J Vis Exp. 2018 Nov 17;(141). doi: 10.3791/58640.

PMID:
30507913
7.

Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2018 Dec;564(7736):439-443. doi: 10.1038/s41586-018-0705-y. Epub 2018 Nov 7. Erratum in: Nature. 2019 Jun;570(7761):E53.

PMID:
30405246
8.

Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties.

Hickey JW, Isser AY, Vicente FP, Warner SB, Mao HQ, Schneck JP.

Biomaterials. 2018 Dec;187:105-116. doi: 10.1016/j.biomaterials.2018.09.029. Epub 2018 Sep 28.

PMID:
30312851
9.

Engineering Platforms for T Cell Modulation.

Hickey JW, Kosmides AK, Schneck JP.

Int Rev Cell Mol Biol. 2018;341:277-362. doi: 10.1016/bs.ircmb.2018.06.003. Epub 2018 Jul 30. Review.

PMID:
30262034
10.

Correction: Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2018 Aug 17;9(64):32401. doi: 10.18632/oncotarget.26018. eCollection 2018 Aug 17.

11.

Soluble MHC class I complexes for targeted immunotherapy.

Schappert A, Schneck JP, Suarez L, Oelke M, Schütz C.

Life Sci. 2018 Sep 15;209:255-258. doi: 10.1016/j.lfs.2018.08.023. Epub 2018 Aug 10. Review.

PMID:
30102903
12.

Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation.

Kosmides AK, Necochea K, Hickey JW, Schneck JP.

Nano Lett. 2018 Mar 14;18(3):1916-1924. doi: 10.1021/acs.nanolett.7b05284. Epub 2018 Feb 28.

PMID:
29488768
13.

Inhibitors of LexA Autoproteolysis and the Bacterial SOS Response Discovered by an Academic-Industry Partnership.

Mo CY, Culyba MJ, Selwood T, Kubiak JM, Hostetler ZM, Jurewicz AJ, Keller PM, Pope AJ, Quinn A, Schneck J, Widdowson KL, Kohli RM.

ACS Infect Dis. 2018 Mar 9;4(3):349-359. doi: 10.1021/acsinfecdis.7b00122. Epub 2018 Jan 8.

14.

ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis.

Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP.

Cancer Immunol Res. 2018 Feb;6(2):151-162. doi: 10.1158/2326-6066.CIR-17-0114. Epub 2017 Dec 20.

15.

Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.

Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.

16.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

17.

Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.

Hickey JW, Vicente FP, Howard GP, Mao HQ, Schneck JP.

Nano Lett. 2017 Nov 8;17(11):7045-7054. doi: 10.1021/acs.nanolett.7b03734. Epub 2017 Oct 10.

PMID:
28994285
18.

Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth.

Kosmides AK, Sidhom JW, Fraser A, Bessell CA, Schneck JP.

ACS Nano. 2017 Jun 27;11(6):5417-5429. doi: 10.1021/acsnano.6b08152. Epub 2017 Jun 7.

PMID:
28589725
19.

Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.

Kosmides AK, Meyer RA, Hickey JW, Aje K, Cheung KN, Green JJ, Schneck JP.

Biomaterials. 2017 Feb;118:16-26. doi: 10.1016/j.biomaterials.2016.11.038. Epub 2016 Dec 2.

20.

Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.

Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP.

Oncotarget. 2016 Oct 18;7(42):68503-68512. doi: 10.18632/oncotarget.11785. Erratum in: Oncotarget. 2018 Aug 17;9(64):32401.

21.

Discovery and Characterization of a Class of Pyrazole Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase.

Concha N, Huang J, Bai X, Benowitz A, Brady P, Grady LC, Kryn LH, Holmes D, Ingraham K, Jin Q, Pothier Kaushansky L, McCloskey L, Messer JA, O'Keefe H, Patel A, Satz AL, Sinnamon RH, Schneck J, Skinner SR, Summerfield J, Taylor A, Taylor JD, Evindar G, Stavenger RA.

J Med Chem. 2016 Aug 11;59(15):7299-304. doi: 10.1021/acs.jmedchem.6b00746. Epub 2016 Jul 20.

PMID:
27379833
22.

Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2.

Poulin MB, Schneck JL, Matico RE, Hou W, McDevitt PJ, Holbert M, Schramm VL.

J Am Chem Soc. 2016 Jun 1;138(21):6699-702. doi: 10.1021/jacs.6b01612. Epub 2016 May 23.

PMID:
27183271
23.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

24.

Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.

Poulin MB, Schneck JL, Matico RE, McDevitt PJ, Huddleston MJ, Hou W, Johnson NW, Thrall SH, Meek TD, Schramm VL.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1197-201. doi: 10.1073/pnas.1521036113. Epub 2016 Jan 19.

25.

Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 + and CD8 + T-cell responses in older adults positively correlates with response size.

Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F, Pawelec G, Wang GC.

Sci Rep. 2016 Jan 18;6:19227. doi: 10.1038/srep19227.

26.

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter CL, Johnson NW, Hann CL, Kruger RG.

Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002.

27.

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP.

ACS Nano. 2015 Jul 28;9(7):6861-71. doi: 10.1021/acsnano.5b02829. Epub 2015 Jul 14.

28.

Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults.

Najarro K, Nguyen H, Chen G, Xu M, Alcorta S, Yao X, Zukley L, Metter EJ, Truong T, Lin Y, Li H, Oelke M, Xu X, Ling SM, Longo DL, Schneck J, Leng S, Ferrucci L, Weng NP.

J Infect Dis. 2015 Oct 15;212(8):1261-9. doi: 10.1093/infdis/jiv202. Epub 2015 Mar 31.

29.

Adoptive T cell immunotherapy for cancer.

Perica K, Varela JC, Oelke M, Schneck J.

Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. doi: 10.5041/RMMJ.10179. eCollection 2015 Jan. Review.

30.

Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation.

Meyer RA, Sunshine JC, Perica K, Kosmides AK, Aje K, Schneck JP, Green JJ.

Small. 2015 Apr;11(13):1519-25. doi: 10.1002/smll.201402369. Epub 2015 Jan 12.

31.

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C.

Clin Cancer Res. 2015 May 1;21(9):2075-83. doi: 10.1158/1078-0432.CCR-14-2696. Epub 2015 Jan 15.

32.

MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.

Schütz C, Zoso A, Peng S, Bennett JD, Schneck JP, Oelke M.

Immun Inflamm Dis. 2014 Nov;2(3):181-92. doi: 10.1002/iid3.35. Epub 2014 Nov 11.

33.

Linking form to function: Biophysical aspects of artificial antigen presenting cell design.

Perica K, Kosmides AK, Schneck JP.

Biochim Biophys Acta. 2015 Apr;1853(4):781-90. doi: 10.1016/j.bbamcr.2014.09.001. Epub 2014 Sep 6. Review.

34.

Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.

Schütz C, Fleck M, Schneck JP, Oelke M.

J Vis Exp. 2014 Aug 11;(90):e51859. doi: 10.3791/51859.

35.

GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.

Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB.

J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. doi: 10.1124/jpet.114.214155. Epub 2014 Apr 30.

PMID:
24784567
36.

Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity.

Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP.

ACS Nano. 2014 Mar 25;8(3):2252-60. doi: 10.1021/nn405520d. Epub 2014 Feb 24.

37.

Sprouty-2 regulates HIV-specific T cell polyfunctionality.

Chiu YL, Shan L, Huang H, Haupt C, Bessell C, Canaday DH, Zhang H, Ho YC, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP.

J Clin Invest. 2014 Jan;124(1):198-208.

38.

Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.

Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Colón M, Dodson CS, Gilbert SA, Greshock J, Jing J, Lu H, McSurdy-Freed JE, Orband-Miller LA, Mills GB, Quinn CJ, Schneck JL, Scott GF, Shaw AN, Waitt GM, Wooster RF, Duffy KJ.

Cancer Metab. 2013 Sep 6;1(1):19. doi: 10.1186/2049-3002-1-19.

39.

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.

Sunshine JC, Perica K, Schneck JP, Green JJ.

Biomaterials. 2014 Jan;35(1):269-277. doi: 10.1016/j.biomaterials.2013.09.050. Epub 2013 Oct 5.

40.

Dispersed three-pulse infrared photon echoes of nitrous oxide in water and octanol.

Shattuck JT, Schneck JR, Chieffo LR, Erramilli S, Ziegler LD.

J Phys Chem B. 2013 Dec 12;117(49):15774-85. doi: 10.1021/jp4065533. Epub 2013 Aug 29.

PMID:
23941277
41.

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, Niemöller M, Assenmacher M, Richter A, Edidin M, Oelke M, Schneck J.

Nanomedicine. 2014 Jan;10(1):119-29. doi: 10.1016/j.nano.2013.06.015. Epub 2013 Jul 24.

42.

Generation of Human iNKT Cell Lines.

Li X, Tsuji M, Schneck J, Webb TJ.

Bio Protoc. 2013 Mar 20;3(6). pii: e418.

43.

Generation of Mouse iNKT Cell Lines.

Li X, Tsuji M, Schneck J, Webb TJ.

Bio Protoc. 2013 Mar 20;3(6). pii: e419.

44.

T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs.

de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET.

PLoS Negl Trop Dis. 2013;7(1):e1938. doi: 10.1371/journal.pntd.0001938. Epub 2013 Jan 31.

45.

Modulation of MHC binding by lateral association of TCR and coreceptor.

Perica K, Bieler JG, Edidin M, Schneck J.

Biophys J. 2012 Nov 7;103(9):1890-8. doi: 10.1016/j.bpj.2012.09.011.

46.

The amino-acid substituents of dipeptide substrates of cathepsin C can determine the rate-limiting steps of catalysis.

Rubach JK, Cui G, Schneck JL, Taylor AN, Zhao B, Smallwood A, Nevins N, Wisnoski D, Thrall SH, Meek TD.

Biochemistry. 2012 Sep 25;51(38):7551-68. doi: 10.1021/bi300719b. Epub 2012 Sep 13.

PMID:
22928782
47.

Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP.

Cancer Res. 2012 Aug 1;72(15):3744-52. doi: 10.1158/0008-5472.CAN-11-2695. Epub 2012 May 30.

48.

Quantum dot fluorescence characterizes the nanoscale organization of T cell receptors for antigen.

Boyle S, Kolin DL, Bieler JG, Schneck JP, Wiseman PW, Edidin M.

Biophys J. 2011 Dec 7;101(11):L57-9. doi: 10.1016/j.bpj.2011.10.028.

49.

Intensity-dependent exciton dynamics of (6,5) single-walled carbon nanotubes: momentum selection rules, diffusion, and nonlinear interactions.

Harrah DM, Schneck JR, Green AA, Hersam MC, Ziegler LD, Swan AK.

ACS Nano. 2011 Dec 27;5(12):9898-906. doi: 10.1021/nn203604v. Epub 2011 Nov 21.

PMID:
22077149
50.

Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors.

Lee JB, Oelke M, Ramachandra L, Canaday DH, Schneck JP.

Immun Ageing. 2011 Aug 16;8:6. doi: 10.1186/1742-4933-8-6.

Supplemental Content

Loading ...
Support Center